Business Context and Reporting Period
Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: MannKind is a biopharmaceutical company in the development stage, focused on the Technosphere Insulin System for diabetes treatment. The lead product is currently in Phase 3 clinical trials in the U.S., Europe, and Latin America. The company has no commercial products and has not generated significant product revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2007 | Six Months Ended June 30, 2006 |
|---|---|---|
| Revenue | $10 | $100 |
| Net Loss | $(145,130) | $(98,310) |
| Net Loss Per Share (Basic & Diluted) | $(1.98) | $(1.98) |
| Research & Development Expenses | $125,268 | $81,271 |
| General & Administrative Expenses | $27,463 | $19,594 |
| Cash and Cash Equivalents (End of Period) | $216,429 | $27,056 |
| Marketable Securities | $67,599 | $116,924 |
| Total Current Assets | $298,610 | $449,547 |
| Senior Convertible Notes (Liability) | $111,523 | $111,267 |
| Accumulated Deficit (Cumulative) | $(932,979) | $(787,849) |
Liquidity: As of June 30, 2007, the company held approximately $284 million in cash, cash equivalents, and marketable securities. Management believes these resources, combined with a $150 million loan arrangement with a principal stockholder, are sufficient to fund operations into the second quarter of 2008.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2007, increased by approximately $46.8 million compared to the same period in 2006, driven primarily by higher operating expenses.
- R&D Expense Growth: Research and development expenses increased by 54% ($44.0 million) year-over-year. This was attributed to expanded clinical development of the Technosphere Insulin System, increased manufacturing costs, higher headcount, and increased stock-based compensation.
- G&A Expense Growth: General and administrative expenses increased by 40% ($7.9 million) due to increased professional fees and salaries.
- Cash Flow: Net cash used in operating activities increased to $127.5 million from $84.7 million in the prior year period. Net cash provided by investing activities decreased to $23.2 million from $54.5 million, largely due to $26.1 million spent on purchasing property and equipment for manufacturing expansion.
- Revenue Decline: Revenue decreased from $100,000 to $10,000, reflecting the cessation of license agreement revenue recognized in the prior period.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Capital Needs
MannKind expects to incur substantial and increasing operating losses for the foreseeable future. The company anticipates needing to raise additional capital through equity/debt sales or strategic collaborations to continue development and commercialization. A shelf registration statement for up to $350 million in securities was filed on August 9, 2007.
Material Weakness in Internal Controls
Management identified a material weakness in internal controls over financial reporting related to the identification and recording of clinical trial costs. This resulted in an overstatement of clinical trial liabilities. Adjustments totaling $6.7 million were made to decrease accrued expenses and $5.8 million to reduce R&D expenses prior to the release of the financial statements. Management is implementing remediation controls.
Risks and Contingencies
- Regulatory Approval: The company must complete Phase 3 trials and obtain FDA approval for the Technosphere Insulin System, which is a combination product (drug and device), potentially complicating the review process.
- Competition: Significant competition exists from inhaled insulin products such as Pfizer's Exubera and Eli Lilly's AIR system.
- Supplier Dependence: The company relies on single suppliers for key components, including insulin (Organon Biosciences N.V.) and the MedTone inhaler (Vaupell, Inc.).
- Legal Proceedings: Litigation with a former Chief Medical Officer was resolved in June 2007 with the dismissal of claims.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $284 million cash position against the projected $300-$400 million capital requirement for the next 12 months.
- Internal Controls: Monitor the remediation progress of the material weakness regarding clinical trial cost accruals and its impact on future financial reporting reliability.
- Clinical Trial Progress: Track the status of Phase 3 safety and efficacy trials, particularly the two-year pulmonary safety study required by the FDA.
- Strategic Collaborations: Assess the likelihood and terms of potential partnerships with pharmaceutical companies, as the company may lack resources to commercialize independently.
- Convertible Notes: Review the terms of the $115 million Senior Convertible Notes due 2013, including conversion rates and potential dilution.